Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suguru Shirotake

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
IJU Case Reports|May 5, 2022
Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinibKoshiro Nishimoto, Suguru Shirotake, Yu Miyama, et al.
Case Reports in Oncology|January 2, 2026
Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case ReportKenta Fujii, Suguru Shirotake, Shohei Yamamura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 3, 2026
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter StudyYuki Endo, Yuma Sakura, Go Kaneko, et al.
In Vivo (Athens, Greece)|December 31, 2024
Proactive Symptom Monitoring by Pharmacists Using a Cancer Patient Support App in Out-patient Oral Multi-kinase Inhibitor Therapy: Feasibility Study of a Small Patient PopulationMaki Todo, Suguru Shirotake, G O Kaneko, et al.
Frontiers in Oncology|November 26, 2024
Case report: a rare clinical presentation of a difficult diagnosis of dedifferentiated liposarcoma showing leiomyosarcoma phenotype in the ileocecal regionTomonori Kawasaki, Tomoaki Tashima, Kojiro Onohara, et al.
Japanese Journal of Clinical Oncology|February 2, 2022
Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancerMinami Omura, Eiji Kikuchi, Keisuke Shigeta, et al.
IJU Case Reports|November 7, 2022
Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcomeKoshiro Nishimoto, Noriaki Lukas Santo, Masato Yonamine, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2025
Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinomaMaki Todo, Yodo Gatate, Shintaro Nakano, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 21, 2022
Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective studyKeita Izumi, Masaharu Inoue, Satoshi Washino, et al.
Urologic Oncology|November 19, 2025
Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter studyYuta Sano, Masaharu Inoue, Satoshi Washino, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
IJU Case Reports|May 5, 2022
Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinibKoshiro Nishimoto, Suguru Shirotake, Yu Miyama, et al.
Case Reports in Oncology|January 2, 2026
Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case ReportKenta Fujii, Suguru Shirotake, Shohei Yamamura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 3, 2026
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter StudyYuki Endo, Yuma Sakura, Go Kaneko, et al.
In Vivo (Athens, Greece)|December 31, 2024
Proactive Symptom Monitoring by Pharmacists Using a Cancer Patient Support App in Out-patient Oral Multi-kinase Inhibitor Therapy: Feasibility Study of a Small Patient PopulationMaki Todo, Suguru Shirotake, G O Kaneko, et al.
Frontiers in Oncology|November 26, 2024
Case report: a rare clinical presentation of a difficult diagnosis of dedifferentiated liposarcoma showing leiomyosarcoma phenotype in the ileocecal regionTomonori Kawasaki, Tomoaki Tashima, Kojiro Onohara, et al.
Japanese Journal of Clinical Oncology|February 2, 2022
Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancerMinami Omura, Eiji Kikuchi, Keisuke Shigeta, et al.
IJU Case Reports|November 7, 2022
Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcomeKoshiro Nishimoto, Noriaki Lukas Santo, Masato Yonamine, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2025
Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinomaMaki Todo, Yodo Gatate, Shintaro Nakano, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 21, 2022
Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective studyKeita Izumi, Masaharu Inoue, Satoshi Washino, et al.
Urologic Oncology|November 19, 2025
Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter studyYuta Sano, Masaharu Inoue, Satoshi Washino, et al.
Pageof 9